Yeah but the same clowns are driving the bus Maz. Thats the concerning part. They continue to underperform and under-deliver. The rush to begin other trials with endpoints other than OS that read out around the time P3 is unblinded also is a concern as they obviously see the ever changing landscape in NSCLC treatments as being a large risk